CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy by Sakamoto, Kathleen M. & Frank, David A.
CREB in the Pathophysiology of Cancer: Implications for
Targeting Transcription Factors for Cancer Therapy
Kathleen M. Sakamoto1,2,3,4,5 and David A. Frank6,7
1Division of Hematology-Oncology, Gwynne Hazen Cherry Memorial Laboratories, Mattel Children's
Hospital UCLA, Jonsson Comprehensive Cancer Center
2Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, Los Angeles,
California
3California Nanosystems Institute, University of California, Los Angeles, Los Angeles, California
4Molecular Biology Institute, University of California, Los Angeles, Los Angeles, California
5Division of Biology, California Institute of Technology, Pasadena, California
6Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
7Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston,
Massachusetts
Abstract
Transcription factors are key regulators of the pattern of gene expression in a cell and directly control
central processes such as proliferation, survival, self-renewal, and invasion. Given this critical role,
the function of transcription factors is normally regulated closely, often through transient
phosphorylation. Although transcription factors are not often directly modified by mutations in
cancer cells, they frequently become activated constitutively through mutations affecting “upstream”
pathways. By continually driving the expression of key target genes, these oncogenic transcription
factors play a central role in tumor pathogenesis. One such transcription factor is the cAMP-
regulatory element-binding protein (CREB), which can be activated through phosphorylation by a
number of kinases, including Akt, p90Rsk, protein kinase A, and calcium/calmodulin-dependent
kinases and regulates genes whose deregulated expression promotes oncogenesis, including
cyclins, Bcl-2 family members, and Egr-1. CREB is overexpressed and constitutively phosphorylated
in a number of forms of human cancer, including acute myeloid leukemia (AML) and non – small
cell lung cancer, and appears to play a direct role in disease pathogenesis and prognosis. Although
transcription factors have not been a central focus of drug development, recent advances suggest that
CREB and other such proteins may be worthwhile targets for cancer therapy.
Background
A key goal in translational cancer research is to understand the molecular abnormalities that
underlie the malignant behavior of a cancer cell, and to target them specifically. Much focus
in recent years has been on kinases as targets for therapy. Although dramatic advances have
been made through the use of kinase inhibitors such as Bcr-Abl inhibitors in chronic myeloid
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leukemia (CML) or epidermal growth factor receptor (EGFR) kinase inhibitors in non–small
cell lung cancer, a number of hurdles have arisen. First, in most forms of cancer, no single
kinase emerges as being activated in a majority of cases. Even where well-defined activating
events in kinases have been described, such as Her2 amplification in breast cancer, these occur
in less than one-third of all patients. Second, even in tumors in which kinase inhibitors have
proven beneficial, resistance to this approach develops frequently, either through mutations in
the target kinase rendering them insensitive to the drug, or through activating mutations in
other kinases that bypass the effects of the inhibitor.
In considering other levels of control that may play an important role in malignant cellular
behavior, and which may be important targets for therapy, increasing attention has focused on
transcription factors. By regulating gene expression, transcription factors are often the final
regulators of such central processes as proliferation, survival, self-renewal, and invasion.
Altered function or expression of a transcription factor may occur as a central component of
the molecular pathogenesis of a tumor. One example is the increased expression of c-myc
driven by chromosomal translocations in Burkitt's lymphoma. Alternatively, transcription
factors that display normal sequence and expression may still be critical mediators of oncogenic
events occurring “upstream.” For example, many kinase and cell-surface receptor-triggered
pathways converge on transcription factors such as NF-κB or STAT family members.
Inhibition of these transcription factors can revert the malignant behavior of many tumor types.
Since normal cells are relatively insensitive to inhibition of these proteins due to redundancies
in normal signaling pathways, inhibitors of these transcription factors hold the potential for
having a very high therapeutic index.
Much of our initial understanding of the role of transcription factors in oncogenesis arose from
studies of normal signal transduction. Growth factors and cytokines can trigger cell-cycle
progression and other cellular events through the rapid and transient activation of transcription
factors that regulate the expression of genes such as cyclins. The malignant phenotype in cancer
is mediated by inappropriate expression of these same genes, often driven by continuous
nonphysiological activation of the transcription factors that normally control their expression.
Thus, critical insight into the role of transcription factor activation in cancer arose from
studying the regulation of genes in response to cytokines under normal conditions. Much of
the initial work on cytokine-mediated control of gene expression, proliferation, survival, and
differentiation was performed in hematopoietic cells due to the relative ease in recapitulating
the biology of these cells in vitro. Furthermore, cytokines often play a direct role in the biology
of hematopoietic malignancies.
The Role of Cytokine Signaling in Leukemogenesis
Acute myeloid leukemia (AML) cells express hematopoietic growth factor receptors and have
increased response to cytokines (1–4). Myeloid cell production is controlled by growth-
stimulatory and -inhibitory molecules such as granulocyte macrophage-colony-stimulating
factor (GM-CSF), granulocyte-colony-stimulating factor (G-CSF), and interleukin-3 (IL-3).
GM-CSF and G-CSF not only stimulate the proliferation and differentiation of myeloid cells,
but they also enhance granulocyte function. Both GM-CSF and G-CSF have been used to
ameliorate chemotherapy- and radiation-induced neutropenia in cancer patients (5,6). Growth
factors such as G-CSF and IL-3 are produced by AML cells, which, in turn, bind to their
receptors and activate signaling pathways that promote cell growth and survival (7–12).
Although GM-CSF and IL-3 are not required for the induction of CML-like myeloproliferative
disease in mice by the BCR/ABL fusion oncoprotein, they may promote survival in
premalignant cells that have yet to fully transform (13). Therefore, growth factor signaling
plays an important role in both normal and neoplastic myeloid cell proliferation and survival.
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The cAMP Response Element-binding Protein Links Cytokine Signaling to
Nuclear Events in Myeloid Cells
Several transcription factors downstream of GM-CSF signaling regulate key target genes
during myelopoiesis. Egr-1 and c-fos are known target genes induced in response to GM-CSF
signaling (6,14–20). CREB is a transcription factor that mediates egr-1 transcription and is
activated by GM-CSF and IL-3 (21–24). This finding provided the first evidence that CREB
played a role in hematopoietic growth factor signal transduction in myeloid cells. CREB is also
phosphorylated in response to thrombopoietin (TPO) in the Human Erythroleukemia (HEL)
cell line (25). Additional studies showed that IL-3 stimulation results in CREB phosphorylation
by a p38-MAP kinase-independent pathway (26–28).
CREB is a Ubiquitous Transcription Factor that Controls Cell Proliferation
and Survival
CREB is a 43 kDa basic/leucine zipper (bZIP) transcription factor that is expressed in most
tissues and is conserved from Drosophila to humans (Fig. 1). CREB binds to the octanucleotide
cAMP response element (CRE) TGANNTCA as a homodimer and as heterodimers in
conjunction with other members of the CREB/ATF superfamily of transcription factors (29,
30). The transcriptional function of CREB becomes activated after its phosphorylation on
serine 133. Reflecting the fact that CREB can integrate signals from a variety of stimuli, this
serine residue can be phosphorylated by a number of serine-threonine kinases. This includes
the cAMP-dependent protein kinase A, calcium, calmodulin-dependent kinases (responding
to calcium fluxes from either the extracellular environment or from internal calcium stores),
or pp90 ribosomal S6 kinase, which is frequently activated downstream of growth factor
receptors (Fig. 1). The phosphorylation of CREB on serine 133 induces its transcriptional
activity by promoting its interaction with the 256 kDa coactivator protein CREB-binding
protein (CBP) (ref. 31). CBP, which is employed as a cofactor by many transcription factors,
stimulates transcription by modulating chromatin through histone acetylation as well as
recruiting the factors necessary for RNA polymerization. CREB has been demonstrated to
promote pleiotropic effects, including cell proliferation, differentiation, and survival of both
neuronal and hematopoietic cells (29,30). CREB, like most transcription factors, can mediate
distinct effects in different cell types or in response to disparate stimuli. This ability of CREB
is likely dependent on cooperative effects with other contemporaneously activated
transcription factors or signaling pathways or on chromatin alterations such as DNA
methylation or histone modification.
CREB ActivatesTarget Genes Downstream of GM-CSF Signaling
CREB target genes function in metabolism, transcription, cell-cycle control, cell survival, DNA
repair, growth control, immune regulation, reproduction, signaling, transport, and cytoskeletal
plasticity (29–31). The fact that CREB-binding sites have been identified in the promoters of
a number of target genes involved in proliferation, differentiation, and survival, including
Bcl-2, Egr-1, and MAP kinase kinase, suggests that CREB has pleiotropic effects on myeloid
cells. This has been confirmed by studies to identify the CREB “regulon” (32).
CREB is a Critical Regulator of Myelopoiesis
In both mouse and humans, CREB is expressed more highly in less differentiated hematopoietic
stem cells (HSCs), e.g., kit+sca+lin-, common myeloid progenitor (CMP), common
granulocyte-macrophage progenitor (GMP), megakaryocyte-erythroid progenitor (MEP),
multipotent progenitor (MPP) cells, compared to more committed cells (33). Knockdown of
CREB in normal myeloid progenitor cells results in decreased myeloid proliferation in colony
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assays and affects short-term engraftment. However, CREB downregulation does not have
effects on long-term hematopoietic engraftment (33). Therefore, although CREB is important
for the regulation of normal myelopoiesis, it does not appear to be necessary for hematopoietic
reconstitution or definitive HSC activity.
Clinical-Translational Advances
CREB overexpression in AML patients
CREB has recently been demonstrated to be overexpressed in leukemic blast cells from patients
with AML compared to normal bone marrow (34–36). Furthermore, CREB overexpression
was associated with a worse prognosis in AML patients compared to patients whose bone
marrow did not overexpress CREB (36–38). Overexpression of CREB protein did not correlate
closely with CREB mRNA levels, suggesting that posttranscriptional mechanisms may
contribute to the elevated expression. Furthermore, activation of CREB in leukemia cells
appears to be cAMP independent (35,39). In all cases in which AML patient bone marrow
samples overexpressed CREB, an increased level of phosphorylated CREB was also observed,
indicating that the protein is functionally active (36). Analysis of primary AML blast cells by
using fluorescence in situ hybridization revealed that there is an increase in copy number of
the CREB gene (36). CREB overexpression also resulted in increased proliferation and survival
of HSCs and myeloid cells in vitro and in vivo (36). Transgenic mice in which CREB is
overexpressed in committed granulocyte and macrophage cells under the control of the hMRP8
promoter develop myeloproliferative disease (splenomegaly and aberrant myelopoiesis), but
not AML, after a latency of 1 year (36). Bone marrow progenitor cells from these mice have
increased replating activity and are hypersensitive to growth factors (36). Therefore, CREB
plays a major role in the regulation of normal myeloid cell proliferation and differentiation and
acts as a proto-oncogene that potentially contributes to leukemogenesis.
CREB knockdown in AML cells inhibits proliferation in vitro and in vivo
CREB downregulation in the AML cell lines TF-1 and K562 resulted in decreased proliferation
in liquid culture with decreased cells in S phase. This appears, at least in part, to be due to a
decrease in the expression of cyclins A1 and D. Both cyclins A and D regulate the G1-to-S
transition and have been demonstrated to be CREB target genes (36). Transplantation of Ba/
F3 pro-B cells transduced with a Bcr-Abl fusion protein containing the T315I mutation and
CREB shRNAs or control scrambled shRNA into SCID mice resulted in delayed leukemia cell
progression and prolonged survival (33). Given the fact that AML cells are more dependent
on CREB than normal myeloid progenitor cells, CREB and CREB-dependent pathways may,
therefore, be potential targets for drug development.
Molecular pathways downstream of CREB
Because CREB is primarily a transcriptional activator, the key to understanding how CREB
regulates normal and aberrant myelopoiesis was to identify target genes downstream of CREB.
One strategy by which to address this issue involved overexpressing CREB in a leukemic cell
line and determining the resultant changes in gene expression (37). Among the most
upregulated genes were Meis1 and Pbx1, at 33-fold and 28-fold, respectively, compared to
parental cells. Studies to determine whether Meis1 and Pbx1 are direct targets of CREB are
currently in progress. Genes that were upregulated or downregulated in CREB knockdown
cells were also analyzed (40). Among the most downregulated genes, interestingly, were
histones. The decreased expression was validated by using RNA interference targeting CREB
in myeloid leukemia cell lines and primary AML cells (40). The role of CREB in regulating
histones is currently under investigation.
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CREB in lung cancer
Altered CREB expression and activity play a role not only in leukemia, but in nonhematologic
malignancies as well. Increased expression and phosphorylation of CREB has been found in
non–small cell lung cancer cell lines, compared to nontransformed bronchial epithelial cell
lines, and in pathologic samples from tumors compared to normal adjacent epithelium (41).
That this finding is likely to be biologically important is suggested by the observation that
patient survival was inversely related to CREB expression and phosphorylation. Interestingly,
this prognostic effect of CREB was found in patients who had never smoked cigarettes rather
than in current or former smokers.
Since CREB is regulated by several distinct pathways that can become activated in cancer cells,
a key question concerns whether the activation of CREB seen in cancer cells is directly driving
the malignant phenotype of the cells, or whether it is merely a byproduct of activation of one
of these upstream pathways. This is a critical question, as CREB would represent a good
molecular target only if it was playing a central role in the biology of the tumor. CREB
activation has been found in non-small-cell lung cancer cell lines, displaying constitutively
activated ERK and pp90RSK and increased expression of Bcl-2 and Bcl-xL (42). A dominant-
negative mutant of CREB and siRNA to knockdown CREB inhibited the proliferation and
survival of NSCLCs. Furthermore, an inhibitor of ERK and pp90RSK activation of CREB
resulted in cell-cycle arrest at G2/M and increased apoptosis, suggesting that CREB is a
potential target for therapy for NSCLC (42). Treatment of lung adenocarcinoma cells with
these drugs resulted in decreased CREB phosphorylation, proliferation, and expression of
cyclin D1 (43). CREB appears to upregulate specific target genes, such as cox-2 in lung
adenocarcinoma cells, through PKA, PKC, and ERK signaling pathways (44).
Therapeutic considerations of targeting transcription factors
Abundant evidence suggests that transcription factors like CREB play a key role in mediating
the malignant behavior of tumor cells. Thus, the two key questions that arise are (1) can these
proteins can be targeted effectively in patients, and (2) what are potential toxicities of therapies
targeting transcription factors.
Pharmaceutical companies have a longstanding and active program in developing kinase
inhibitors, nearly all of which focus on the same site, the ATP-binding domain. The structures
of these pockets have been well characterized, and drug-like molecules with molecular weights
of approximately 500 daltons can bind to these sites with high specificity. Transcription factors,
by contrast, provide a more challenging target. The surfaces of interaction that they employ in
protein-protein and protein-DNA interactions are somewhat larger. Furthermore, as with
CREB, transcription factors are usually members of large families, and the likely toxicity of
drugs targeting these proteins is much greater if multiple family members are affected.
However, notable advances have been made in the area of developmental therapeutics targeting
transcription fatcors. Much of this advance has come from academic laboratories, perhaps
reflecting the relative lack of interest of pharmaceutical and biotechnology companies in these
proteins. Two types of strategies have been particularly fruitful. The first has been structure-
based approaches in which inhibitors of specific domains are targeted. This has included
inhibiton of transcription factor phosphorylation, nuclear localization, DNA binding, and
coactivator recruitment. The second approach has been to establish screening systems often
relying on a transcription-based readout. For example, cell lines have been established in which
the expression of reporter proteins such as luciferase, green fluorescent protein (GFP), or
secreted alkaline phosphatase (SEAP) are under the control of a specifc transcription factor.
Large chemical libraries can then be screened for modulators of the pathway, while
counterscreening against an unrelated pathway to exclude nonspecific compounds. This
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approach, which has yielded compounds that can modulate a number of transcription factors
(45,46), provides proof of concept that such specific inhibitors can be developed. In addition,
this “chemical biology” approach provides great insight into mechanisms by which these
pathways can be modulated therapeutically.
Conclusions
Starting with basic questions as to how gene expression in the nucleus is modulated by changes
in the intracellular and extracellular environment, CREB has been identified as an important
transcription factor in normal cellular function. The additional finding that CREB can mediate
the effects of cytokines provided insight into how this protein plays a critical role in the
homeostasis of complex systems such as hematopoiesis. This work then led to our
understanding of the role that CREB can play in both hematologic and nonhematologic
malignancies, and how it may be a target for rational therapy. This serves as an additional
example of how basic advances can ultimately lead to an enhanced understanding of the
pathogenesis of cancer, and new strategies for targeted rational therapy.
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CREB integrates signals from diverse cellular events to regulate the transcription of key target
genes. The transcriptional function of CREB becomes activated when it is phosphorylated on
serine 133, which triggers the recruitment of transcriptional coactivators such as CREB-
binding protein (CBP). The phosphorylation of CREB can be catalyzed by a variety of kinases,
including calcium/calmodulin-dependent (Cam) kinases, which can be activated by calcium
fluxes from extracellular or intracellular compartments; Akt or p90Rsk, which can be activated
by distinct pathways downstream of growth factor receptors; and protein kinase A, which is
activated by cAMP. Genes regulated by CREB can control critical cellular processes, and thus
the inappropriate activation of CREB can contribute to the pathogenesis of a variety of cancers.
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